Company: RPTX
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001193125-25-283336
Chunk: 3

Company: Repare Therapeutics Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Item 1A
Chunk 3
---
 effect on our business, operating results and financial condition and could cause a decline in the price of our common shares.

Our shareholders may not receive any payment on the CVR and the CVR may expire valueless.

If the proposed transactions are completed, the holders of our common shares, RSUs and in the money options will be entitled to receive one CVR per share, representing the right to receive, subject to the terms and conditions of the CVR Agreement, a pro rata portion of contingent future cash payments. In the event that no CVR Proceeds (as defined in and determined in accordance with the CVR Agreement) become payable prior to the Expiration Date, holders of the CVRs will not receive any payment pursuant to the CVR Agreement. The CVRs will not be transferable, except in the limited circumstances specified in the CVR Agreement, will not have any voting or dividend rights, and will not represent any equity or ownership interest in us or any of our affiliates, and interest will not accrue on any amounts potentially payable on the CVRs. Accordingly, the right of any of our shareholders to receive any future payment on or derive any value from the CVRs will be contingent solely upon the occurrence of a disposition, as outlined above, and if no such dispositions or payments are achieved for any reason within the time periods specified in the CVR Agreement, no payments will be made under the CVRs, and the CVRs will expire valueless.